High expression of ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) is associated with poor prognosis in lung adenocarcinoma
Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: A population-based study
Clinicopathologic characteristics and clinical outcomes of pure type and mixed type of tubular carcinoma of the breast: A single-institution cohort study
3 reasons to join M3 India Market Research Panel
- Contribute to improvements in Healthcare by sharing your insights
- Earn rewards in your free time
- Secure: We never share your personal information without your permission
Over 4 million Doctors across 9 countries
trust M3 Group for their daily practice.
M3 India is a Joint Venture between M3 Inc. Japan and Health Care at Home India Pvt. Ltd.
By leveraging internet based technologies, this initiative will expand access to information and enhance communication in the Indian healthcare sector.